Vepugratinib (LY3866288)

Vepugratinib · Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Vepugratinib (LY3866288), covering 2026-04-17 to 2026-04-17. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract [Phase 3]